Drug Trial Radar · NCT05078593
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Oct 11, 2021
Primary completion
Aug 18, 2023
Study completion Aug 18, 2023
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
Conditions
- Solid Tumor, Adult
- Lymphoma
Interventions
HLX26Drug
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Dose-Limiting Toxicity (DLT) of HLX26 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid Tumors or LymphomasTime frame: from day1 to day 21
- The Maximum Tolerated Dose (MTD) of HLX26 within 3 weeks after the first Administration in patients with Advanced/Metastatic SolidTime frame: from day1 to day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.